Skip to main content

The ability of COVID-19 tests to detect emerging genetic variants of SARS-CoV-2

The TGA is undertaking a post-market review of all Point of Care and Laboratory tests included in the ARTG, which are intended to identify patients with COVID-19, to ensure they can detect the emerging SARS-CoV-2 genetic variants and remain accurate.

Last updated

Help us improve the Therapeutic Goods Administration site